Vaccine Development in the Time of COVID-19: The Relevance of the Risklick AI to Assist in Risk Assessment and Optimize Performance.
COVID-19
artificial intelligence
pharmacology
risk analysis
vaccine
Journal
Frontiers in digital health
ISSN: 2673-253X
Titre abrégé: Front Digit Health
Pays: Switzerland
ID NLM: 101771889
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
07
2021
accepted:
24
09
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
20
11
2021
Statut:
epublish
Résumé
The 2019 coronavirus (COVID-19) pandemic revealed the urgent need for the acceleration of vaccine development worldwide. Rapid vaccine development poses numerous risks for each category of vaccine technology. By using the Risklick artificial intelligence (AI), we estimated the risks associated with all types of COVID-19 vaccine during the early phase of vaccine development. We then performed a postmortem analysis of the probability and the impact matrix calculations by comparing the 2020 prognosis to the contemporary situation. We used the Risklick AI to evaluate the risks and their incidence associated with vaccine development in the early stage of the COVID-19 pandemic. Our analysis revealed the diversity of risks among vaccine technologies currently used by pharmaceutical companies providing vaccines. This analysis highlighted the current and future potential pitfalls connected to vaccine production during the COVID-19 pandemic. Hence, the Risklick AI appears as an essential tool in vaccine development for the treatment of COVID-19 in order to formally anticipate the risks, and increases the overall performance from the production to the distribution of the vaccines. The Risklick AI could, therefore, be extended to other fields of research and development and represent a novel opportunity in the calculation of production-associated risks.
Identifiants
pubmed: 34796360
doi: 10.3389/fdgth.2021.745674
pmc: PMC8593331
doi:
Types de publication
Journal Article
Langues
eng
Pagination
745674Informations de copyright
Copyright © 2021 Haas, Borisov, Alvarez, Ferdowsi, von Mayenn, Teodoro and Amini.
Déclaration de conflit d'intérêts
QH, NB, LM, and PA are work for Risklick. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nature. 2020 Jun;582(7811):167-168
pubmed: 32504015
Virus Res. 2021 Aug;301:198454
pubmed: 34015363
Lancet Infect Dis. 2021 Apr;21(4):e103-e109
pubmed: 33306980
NPJ Vaccines. 2021 Apr 22;6(1):63
pubmed: 33888722
Eur J Pharmacol. 2021 Feb 5;892:173751
pubmed: 33245898
J Nanobiotechnology. 2021 Feb 25;19(1):59
pubmed: 33632278
J Med Internet Res. 2021 Sep 17;23(9):e30161
pubmed: 34375298
Camb Q Healthc Ethics. 2021 Jan;30(1):59-68
pubmed: 32498742
Can J Microbiol. 2021 Mar;67(3):189-212
pubmed: 33264067
SN Comput Sci. 2020;1(4):206
pubmed: 33063049
Immunity. 2020 Apr 14;52(4):583-589
pubmed: 32259480
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
Sci Transl Med. 2020 Nov 4;12(568):
pubmed: 33077678
Clin Drug Investig. 2021 Jun;41(6):499-509
pubmed: 33754328
Health Technol (Berl). 2021 Jun 7;:1-9
pubmed: 34123697
Nat Med. 2021 Jun;27(6):1055-1061
pubmed: 33875890
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067511
Nat Hum Behav. 2020 Jul;4(7):666-669
pubmed: 32576981
Lancet. 2020 Jun 6;395(10239):1751-1752
pubmed: 32505245
Pharmacology. 2021;106(5-6):244-253
pubmed: 33910199
J Pharm Sci. 2021 Mar;110(3):997-1001
pubmed: 33321139
AAPS PharmSciTech. 2020 Aug 5;21(6):225
pubmed: 32761294
Clin Immunol. 2021 Jan;222:108634
pubmed: 33217545